Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Srdan Verstovsek

Medical Oncology Houston, TX Medical Doctor

NPI 1598864100 CMS profile 892588

1515 Holcombe Blvd, Houston, TX 77030

Open in the dashboard

General payments

$463,760

217 records reported · program years 2019–2024

Research payments

$14,072

Paid to them · 9 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,428,873 paid to institutions, not to them · program years 2019–2025

Through program year 2024, Srdan Verstovsek of Houston, TX is reported in the CMS Open Payments database as having received $463,760 across 217 general payments and $14,072 in research payments paid to them. Separately, studies naming them as principal investigator received $2,428,873 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Medical Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2024 Research $1,057 1
2023 General $68,441 16
2023 Research $6,753 2
2022 General $138,597 63
2022 Research $2,250 1
2021 General $111,187 49
2021 Research $1,500 1
2020 General $98,633 46
2020 Research $150 1
2019 General $46,904 43
2019 Research $2,363 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Srdan Verstovsek
  • Medical Oncology median
  • Middle half of Medical Oncology
  • National median

In program year 2025, general payments to Srdan Verstovsek were reported at $0. Among 3,316 Medical Oncology profiles paid that year, the median was $1,128 and the middle half received between $147 and $5,675.

Show as a table
Year Srdan Verstovsek Medical Oncology median Middle half National median
2019 $46,904 $968 $140–$6,658 $163
2020 $98,633 $747 $102–$5,891 $114
2021 $111,187 $430 $50–$4,098 $132
2022 $138,597 $812 $127–$4,907 $149
2023 $68,441 $957 $144–$5,248 $160
2024 $0 $1,042 $149–$5,650 $164
2025 $0 $1,128 $147–$5,675 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Incyte Corporation $189,391 84 payments
  2. Celgene Corporation $36,396 27 payments
  3. Novartis Pharmaceuticals Corporation $31,855 14 payments
  4. GlaxoSmithKline, LLC. $30,841 14 payments
  5. Novartis Pharma AG $27,709 11 payments
  6. NS Pharma, Inc. $22,400 6 payments
  7. E.R. Squibb & Sons, L.L.C. $20,413 8 payments
  8. Karyopharm Therapeutics Inc. $19,680 2 payments
  9. CTI BioPharma Corp. $18,429 6 payments
  10. Ipsen Biopharmaceuticals, Inc $16,400 11 payments
  11. Other $50,247 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Consulting Fee $297,143 111 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $127,545 33 payments
  3. Honoraria $22,863 7 payments
  4. Travel and Lodging $8,404 22 payments
  5. Education $5,343 2 payments
  6. Food and Beverage $2,463 42 payments
Products named General payments · program years 2019–2024
  1. JAKAFI Hematology/Oncology $29,462 20 payments
  2. JAKAFI Oncology $21,317 7 payments
  3. XPOVIO $19,680 2 payments
  4. Vonjo $18,429 6 payments
  5. BESREMI $14,264 9 payments
  6. INREBIC $10,718 8 payments
  7. RYDAPT $10,231 5 payments
  8. JAKAVI_JAKAFI_ONCOLOGY $8,265 4 payments
  9. PEMAZYRE $7,380 2 payments
  10. REBLOZYL $6,826 3 payments
  11. Other $41,215 23 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. F. Hoffmann-La Roche AG $7,809 3 payments
  2. Celgene Corporation $6,113 5 payments
  3. Novartis Pharmaceuticals Corporation $150 1 payment

Records

226 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Medical Oncology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record